Head-to-head evidence
Avacincaptad pegol vs Cemdisiran
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: Complement C5 · full Age-Related Macular Degeneration pipeline
Avacincaptad pegol · Izervay
Marketed by Astellas Pharma
NCT04435366 · Phase 3 · completed
This was a randomized, double-blind (participant, evaluating investigator, reading center, and sponsor masked), sham-controlled, parallel-group Phase 3 trial with 448 participants randomized to avacincaptad pegol or sham. The hard primary endpoint of geographic atrophy growth rate on fundus autofluorescence was met: avacincaptad pegol slowed GA enlargement compared with sham at Month 12 (LS mean 0.336 vs 0.392 mm/year; difference 0.056; 95% CI 0.016–0.096; p=0.0064), and both Month 24 co-primary comparisons also favored avacincaptad pegol. Secondary visual acuity and visual-function questionnaire endpoints did not show a significant benefit, but the primary structural endpoint was statistically significant.
Next expected readout: June 2027 · NCT06970665 (registry estimate)
Cemdisiran
Developed by Regeneron Pharmaceuticals under a licence from Alnylam Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: July 2028 · NCT06541704 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Avacincaptad pegol's landscape · Cemdisiran's landscape